exp3174 has been researched along with warfarin in 1 studies
| Studies (exp3174) | Trials (exp3174) | Recent Studies (post-2010) (exp3174) | Studies (warfarin) | Trials (warfarin) | Recent Studies (post-2010) (warfarin) |
|---|---|---|---|---|---|
| 236 | 29 | 43 | 36,573 | 2,143 | 14,728 |
| Protein | Taxonomy | exp3174 (IC50) | warfarin (IC50) |
|---|---|---|---|
| Vitamin K epoxide reductase complex subunit 1 | Homo sapiens (human) | 0.0088 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arslanbekova, SM; Golukhova, EZ; Kazakov, RE; Kuznetsova, EV; Smirnov, VV; Sychev, DA | 1 |
1 other study(ies) available for exp3174 and warfarin
| Article | Year |
|---|---|
[Relationship between warfarin dosing and activity of CYP2C9 assessed by the content of losartan and its metabolite E-3174 in the urine of patients with mechanical prosthetic heart valves].
Topics: Adult; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cardiovascular Agents; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Drug Monitoring; Female; Genotype; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Humans; Imidazoles; Losartan; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Postoperative Period; Tetrazoles; Warfarin | 2013 |